These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9434579)

  • 41. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats.
    Babu PV; Sabitha KE; Srinivasan P; Shyamaladevi CS
    Pharmacol Res; 2007 May; 55(5):433-40. PubMed ID: 17336542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling.
    Csiszar A; Ungvari Z
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H475-6. PubMed ID: 18599592
    [No Abstract]   [Full Text] [Related]  

  • 43. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
    Schmidt AM; Stern DM
    Trends Endocrinol Metab; 2000 Nov; 11(9):368-75. PubMed ID: 11042467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
    Yamagishi S; Matsui T
    Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients.
    Katakami N; Matsuhisa M; Kaneto H; Yamasaki Y
    Diabetes Care; 2006 Feb; 29(2):469. PubMed ID: 16443918
    [No Abstract]   [Full Text] [Related]  

  • 46. Advanced glycosylation end products in peritoneal tissue with different solutions.
    Dobbie JW
    Perit Dial Int; 1997; 17 Suppl 2():S27-30. PubMed ID: 9163793
    [No Abstract]   [Full Text] [Related]  

  • 47. [A young woman who wanted to take her diabetes seriously].
    Waehre T; Odberg T; Kapelrud H
    Tidsskr Nor Laegeforen; 1999 May; 119(13):1897-900. PubMed ID: 10382337
    [No Abstract]   [Full Text] [Related]  

  • 48. AGE in micro- and macroangiopathy.
    Lapolla A; Traldi P; Fedele D
    Contrib Nephrol; 2001; (131):10-21. PubMed ID: 11125555
    [No Abstract]   [Full Text] [Related]  

  • 49. Diabetes and advanced glycation endproducts.
    Vlassara H; Palace MR
    J Intern Med; 2002 Feb; 251(2):87-101. PubMed ID: 11905595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Nakatani Y; Ohtoshi K; Hayaishi-Okano R; Kosugi K; Hori M; Yamasaki Y
    Diabetes Care; 2005 Nov; 28(11):2716-21. PubMed ID: 16249545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycation index of hair for non-invasive estimation of diabetic control.
    Kobayashi K; Igimi H
    Biol Pharm Bull; 1996 Apr; 19(4):487-90. PubMed ID: 8860944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advanced glycation endproducts and their receptor: do they play a role in diabetic cardiomyopathy?
    Arai M
    J Mol Cell Cardiol; 2002 Oct; 34(10):1305-8. PubMed ID: 12392990
    [No Abstract]   [Full Text] [Related]  

  • 53. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
    Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RAGE: a novel cellular receptor for advanced glycation end products.
    Schmidt AM; Hori O; Cao R; Yan SD; Brett J; Wautier JL; Ogawa S; Kuwabara K; Matsumoto M; Stern D
    Diabetes; 1996 Jul; 45 Suppl 3():S77-80. PubMed ID: 8674899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease.
    Yamagishi S
    Curr Pharm Des; 2008; 14(10):939. PubMed ID: 18473842
    [No Abstract]   [Full Text] [Related]  

  • 56. Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy.
    Yoon YW; Kang TS; Lee BK; Chang W; Hwang KC; Rhee JH; Min PK; Hong BK; Rim SJ; Kwon HM
    Exp Mol Med; 2008 Aug; 40(4):398-406. PubMed ID: 18779652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shifting the disease management paradigm from glucose: what are the pros?
    Stirban A; Tschoepe D; Stratmann B
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S349-52. PubMed ID: 19875579
    [No Abstract]   [Full Text] [Related]  

  • 58. Oxidative stress, protein glycation and nutrition--interactions relevant to health and disease throughout the lifecycle.
    Vlassopoulos A; Lean ME; Combet E
    Proc Nutr Soc; 2014 Aug; 73(3):430-8. PubMed ID: 24877772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetic nephropathy and advanced glycation end products.
    Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
    Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
    [No Abstract]   [Full Text] [Related]  

  • 60. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update.
    Piarulli F; Sartore G; Lapolla A
    Acta Diabetol; 2013 Apr; 50(2):101-10. PubMed ID: 22763581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.